| Immune checkpoint inhibitors |
Hypophysitis (ipilimumab, nivolumab) |
| Primary thyroid dysfunction (ipilimumab, nivolumab, pembrolizumab) |
| Tyrosine kinase inhibitors |
Hypothyroidism (sunitinib, sorafenib, axitinib, pazopanib, vandetanib, motesanib) |
| Increased levothyroxine requirement in thyrodectomised patients (imatinib, sorafenib, motesanib) |
| Interferon-α |
Hypothyroidism, destructive thyroiditis |
| Interleukin-2 |
Hypothyroidism |
| Alemtuzumab |
Graves’ disease |
| Thalidomide analogues |
Hypothyroidism, ischaemic thyroiditis (thalidomide, lenalidomide) |
| Radioiodine-based cancer therapy |
Hypothyroidism, radiation thyroiditis |
| Bexarotene |
Central hypothyroidism |
| Conventional agents |
Alteration in thyroid binding proteins (not clinically relevant) (mitotane, 5-fluorouracil, oestrogens, tamoxifen, podophyllin, L-asparaginase) |
